This article previews some formulation topics discussed in the Pharma Fundamentals series, which aims to enhance learning for professionals in pharmaceutical drug development and manufacturing. It is ...
MELBOURNE, Australia, Sept. 28, 2025 (GLOBE NEWSWIRE) -- CLINUVEL today announced that it is advancing new sustained-release liquid drug formulations in a preclinical program evaluating various drug ...
Researchers at the University of Toronto say they have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations. The potential for machine ...
Predicting Bioequivalence During Generic Drug Formulation. Small variations in formulation can affect bioequivalence. However ...
Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a biotechnology company developing novel ...
Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies New ...
Access Pharmaceuticals, Inc. (OTCBB: ACCP), announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its ...
The pharmaceutical development of a cardiovascular polypill presents several unique challenges. The selection of the type and number of active drugs to be incorporated requires important consideration ...
Industry experts discuss the benefits of utilizing contract development and contract research organizations in drug discovery and development. Drug discovery can involve extensive research to identify ...
The protein therapeutics market totaled $63 billion in 2007 ($39 billion in the U.S. alone) and is expected to reach $87 billion by 2010, according to a report by Kalorama Information—“Protein ...
(MENAFN- EIN Presswire) EINPresswire/ -- The global Oral Solid Dosage (OSD) Pharmaceutical Formulation Market is set to surge from USD 779.44 Billion in 2024 to USD 1,349.27 Billion by 2032, at a 7.1% ...
first biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for peptides, melanocortins aim to predict drug release kinetics from new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results